Chemical Namedefibrotide sodium
Dosage FormInjection (intravenous; 200 mg/2.5 mL)
Drug ClassOligonucleotides
CompanyJazz Pharmaceuticals Inc.
Approval Year2016


  • To treat adults and children who develop hepatic veno-occlusive disease with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantation.
Last updated on 10/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Defitelio (defibrotide sodium) Prescribing Information 2016Jazz Pharmaceuticals, Inc. Palo Alto, CA